



The following report details mergers and acquisitions activity in the biotech sector in July 2015 using data from the Zephyr database.

It focuses on global deals activity by target company within the biotech sector.

Click [here](#) to access the raw data in an Excel spreadsheet.

- 1 Private Equity, Venture Capital and Development Capital
- 2 All deals: Mergers, Acquisitions, Joint Ventures
- 3 IPOs

Biotech investment growth sustained in July

The value of private equity, venture capital and development capital (PE, VC and DC) investment in the global biotechnology sector increased for the second month in a row in July to reach its highest point of 2015 so far.

Deals worth an aggregate USD 745 million were announced over the four weeks, up 74 per cent on USD 429 million in June and almost five times higher than USD 151 million in May. Volume also advanced for the second successive month to 23 deals (May: 13; June: 22).


In a 12-month comparison, value was significantly higher than the USD 158 million-worth of investment, and volume up 15 per cent on the 20 deals announced in July 2014.

A surge in the value of PE, VC and DC investment targeting UK biotech companies boosted global results.

Private equity, venture capital and development capital deals by volume and value

Announced date	No of deals	Total deal value (mil USD)
Jul-15	23	745
Jun-15	22	429
May-15	13	151
Apr-15	24	516
Mar-15	21	225
Feb-15	24	260
Jan-15	27	516
Dec-14	23	2,621
Nov-14	17	314
Oct-14	28	327
Sep-14	24	248
Aug-14	15	441
Jul-14	20	158

Private equity, venture capital and development capital deals by volume and value



UK cancer treatments developer targeted in top deal by value

Immunocore, an Oxfordshire-based research services company focused on developing treatments for cancer, viral infections and autoimmune disease, raised USD 320 million in its first round of funding. Investors included Woodford Investment Management, Malin Corporation and Eli Lilly, and proceeds will be used to advance Immunocore's pipeline of biologics called Immune mobilising mTCR against cancer.

This deal was worth almost twice as much as the second-highest deal by value, which again targeted a UK company. BBI Diagnostics Group 2, a diagnostics reagents developer based in Cardiff, was acquired by Exponent Private Equity for USD 164 million, in a rare private equity buyout in the biotech sector.

In all, UK companies were targeted in four of the top 20 deals by value, with companies based in the US, France, Switzerland, Hungary, China, Japan, Sweden, Spain and Colombia also targeted.

UK leads by value, US by volume

The value of PE, VC and DC investment targeting the UK biotech sector soared in July to USD 518 million, a huge increase on USD 5 million the previous month and the highest result recorded in the last 12 months under review.

By contrast, investment in the US almost halved month-on-month from USD 231 million in June to USD 122 million.

The US led by volume with 6 transactions, half the 12 deals announced in June, and the lowest recorded in the past 12 months. Volume targeting UK biotech companies doubled over the four weeks to 4 transactions, while third-placed China increased at the same rate, from 1 deal in June to 2.

Top private equity, venture capital and development capital deals by value

	Deal value (mil USD)	Deal type	Target	Target business description	Target country	Fund Manager/General Partner	Deal status
1.	320	Minority stake	Immunocore Ltd	Immuno-oncology pharmaceuticals developer, Immuno-oncology research services	GB	Eli Lilly and Company; RTW Investments LLC; Woodford Investment Management LLP; Malin Corporation plc	Completed
2.	164	IBO 100%	BBI Diagnostics Group 2 plc	Diagnostic reagents developer	GB	Exponent Private Equity LLP	Announced
3.	55	Minority stake	RaNA Therapeutics Inc.	RNA novel drugs developer company	US	Monsanto Company; The Baupost Group LLC; Brookside Capital LLC; Pfizer Venture Investments; Partners Healthcare System Inc.; SR One Ltd; Atlas Venture Inc.; Omega Fund Management (US) Inc.; MS Ventures; Rock Springs Capital Management LP; Leerink Partners LLC; Merck & Company Inc.	Completed
4.	45	Minority stake	Ginkgo Bioworks Inc.	Biological research developer	US	Felicis Ventures; Y Combinator LLC; OS Fund LLC	Completed
5.	36	Minority stake	GenSight Biologics SA	Retinal degenerative diseases biopharmaceuticals developer	FR	Index Venture Management SA; Fidelity Management & Research Company; Versant Venture Management LLC; Jennison Associates LLC; Perceptive Advisors LLC; Abingworth LLP; Novartis Venture Funds; Sphera Funds Management Ltd; BPI Groupe SA	Completed
6.	33	Minority stake	KalVista Pharmaceuticals Ltd	Molecule plasma kallikrein inhibitors developer	GB	Novo A/S; SV Life Sciences Advisers LLP; RA Capital Management LLC; Longwood Founders Fund LP	Completed
7.	21	Minority stake	InSphero AG	Organotypic biological new drug testing microtissues manufacturer	CH		Completed
8.	20	Capital Increase 32%	CymaBay Therapeutics Inc.	Clinical-stage biopharmaceuticals developer, Clinical-stage biopharmaceuticals manufacturer	US	Abingworth LLP	Completed
9.	19	Minority stake	PIQUR Therapeutics AG	Cancer patients oncology biopharmaceuticals developer, Cancer patients oncology biopharmaceuticals manufacturer	CH	Versant Venture Management LLC	Completed
10.	9	Minority stake	Organica Technologiak Zrt	Biological waste water treatment and recycling solutions provider	HU	The International Finance Corporation; Gamma Investors LLC; XPV Capital Corporation; IDInvest Partners	Completed

Top private equity, venture capital and development capital deals by value (cont'd)

	Deal value (mil USD)	Deal type	Target	Target business description	Target country	Fund Manager/General Partner	Deal status
11.	5	Minority stake 6%	Genesis Healthcare. Co	Genetic testing kits developer	JP	Mitsui & Co., Ltd; Founders Fund Management LLC	Completed
12.	4	Minority stake	InnaVirVax SAS	Biopharmaceuticals developer	FR	Fa Diese 2 SAS; G1J Ile de France; Pradeyrol Developpement; Fonds Regional de Co-Investissement d'Ile-de-France SASU; BPI Groupe SA	Completed
13.	4	Minority stake 2%	Shenzhen Hornetcorn Biotechnology Co., Ltd	Biotechnology engineering services	CN	Beijing Zhongrong Dingxin Investment Management Co., Ltd	Pending
14.	3	Minority stake	Pharmanest AB	Gynecology and obstetrics pharmaceutical products development services	SE		Completed
15.	3	Minority stake 10%	Guangdong Shinyee Marine Biology Engineering Corp.	Dried seafood product manufacturer, Marine biological products development services, Seafood condiment and other marine biological products manufacturer	CN	Dongzheng Jinxin Investment Management Co., Ltd; Beijing Tianxing Capital Investment Management Co., Ltd; Guangzhou Shanhua Investment Management Co., Ltd	Pending
16.	2	Minority stake	Rubicon Genomics Inc.	Genetic analysis technology developer	US	Research Corporation Technologies Inc.; BroadOak Capital Partners LLC	Completed
17.	1	Minority stake	Oxford Genetics Ltd	Modular DNA pharmaceutical plasmids manufacturer	GB	Mercia Fund Management Ltd	Completed
18.	0	Minority stake	SM GENOMICS SL	Professional sports genetics researcher	ES		Announced
19.	0	Minority stake	Theron Pharmaceuticals Inc.	Chronic respiratory biotechnology products developer	US		Completed
20.	0	Minority stake	Ipsum	Neurological and tropical diseases pharmaceutical research developer	CO		Completed

Target countries by volume: private equity, venture capital and development capital deals

Target country	Jul-14	Jun-15	Jul-15
US	12	12	6
UK	3	2	4
China	0	1	2
France	2	0	2
Switzerland	0	0	2
Sweden	0	0	2
Colombia	0	0	1
Germany	2	0	1
Spain	1	0	1
Japan	0	0	1
Hungary	0	0	1

Target countries by value: private equity, venture capital and development capital deals

Target country	Jul-14 (mil USD)	Jun-15 (mil USD)	Jul-15 (mil USD)
UK	5	5	518
US	136	231	122
Switzerland	0	0	40
France	2	0	40
Hungary	0	0	9
China	0	4	7
Japan	0	0	5
Sweden	0	0	3

Private equity, venture capital and development capital investors

Company name	Number of deals	Number with consideration	Total deal value (mil USD)	Average deal value (mil USD)
1 RTW Investments LLC	1	1	320	320
2 Woodford Investment Management LLP	1	1	320	320
3 Malin Corporation plc	1	1	320	320
4 Exponent Private Equity LLP	1	1	164	164
5 Abingworth LLP	2	2	56	28
6 Leerink Partners LLC	1	1	55	55
7 SR One Ltd	1	1	55	55
8 Atlas Venture Inc.	1	1	55	55
9 Pfizer Venture Investments	1	1	55	55
10 Monsanto Company	1	1	55	55
11 The Baupost Group LLC	1	1	55	55
12 Brookside Capital LLC	1	1	55	55
13 Merck & Company Inc.	1	1	55	55
14 MS Ventures	1	1	55	55
15 Omega Fund Management (US) Inc.	1	1	55	55
16 Rock Springs Capital Management LP	1	1	55	55
17 Versant Venture Management LLC	2	2	55	27
18 Felicis Ventures	1	1	45	45
19 OS Fund LLC	1	1	45	45
20 Y Combinator LLC	1	1	45	45

M&A value doubles year-over-year

Growth seen in PE, VC and DC investment was replicated in overall mergers and acquisitions (M&A) targeting the global biotech sector in July.


Value rose for the second month in a row to USD 10,958 million (May: USD 736 million; June: USD 4,165 million) and was double the USD 5,414 million a year earlier. Volume weakened slightly month-on-month from 91 transactions in June to 89, but was 14 per cent higher than the 78 deals signed off at the same time last year.

The huge increase in value was attributable to a single deal. Celgene made a take-private offer worth USD 7,200 million for Receptos, a Californian company engaged in the development of treatments for immune and metabolic diseases, which accounted for two-thirds of all M&A value in the biotech sector in July.

Deals by volume and value

Announced date	No of deals	Total deal value (mil USD)
Jul-15	89	10,958
Jun-15	91	4,165
May-15	59	736
Apr-15	83	37,247
Mar-15	98	24,033
Feb-15	80	2,165
Jan-15	86	9,216
Dec-14	88	15,780
Nov-14	78	4,045
Oct-14	92	1,349
Sep-14	79	3,620
Aug-14	65	2,737
Jul-14	78	5,414

Deals by volume and value



Top 20 deals by value

	Deal value (mil USD)	Deal type	Target	Target business description	Target country	Acquiror	Deal status
1.	7,200	Acquisition 100%	Receptos Inc.	Immune and metabolic diseases biopharmaceuticals developer, Immune and metabolic diseases biotechnology research and development services	US	Celgene Corporation	Announced
2.	886	Acquisition 100%	Changchun Changsheng Biotechnology Co., Ltd	Biological vaccines development services, Biological vaccines manufacturer	CN	LianYunGang HuangHai Machinery Co., Ltd	Pending
3.	560	Acquisition 100%	Naurex Inc.	Depression and other CNS disorders treatment manufacturer, Depression and other CNS disorders treatment research and developer	US	Allergan plc	Announced
4.	320	Minority stake	Immunocore Ltd	Immuno-oncology pharmaceuticals developer, Immuno-oncology research services	GB	Eli Lilly and Company; Existing Investors; New Investors; RTW Investments LLC; Woodford Investment Management LLP; Malin Corporation plc	Completed
5.	319	Acquisition 100%	Coretherapix SL	Cardiology-focused cell therapy company, Ischemic cardiovascular disease treatment products developer	ES	TiGenix NV	Completed
6.	193	Capital Increase 8%	Exact Sciences Corporation	Biological early detection of colorectal cancer pharmaceutical preparations manufacturer, Biological early detection of colorectal cancer research services	US	Robert W Baird & Company Inc.; Jefferies LLC	Completed
7.	164	IBO 100%	BBI Diagnostics Group 2 plc	Diagnostic reagents developer	GB	Exponent Private Equity LLP	Announced
8.	144	Capital Increase 15%	Dynavax Technologies Corporation	Clinical-stage biopharmaceutical products manufacturer, Clinical-stage biopharmaceutical research and development services	US		Completed
9.	105	Capital Increase 43%	ReNeuron Group plc	Stem cell therapies development services	GB	Institutional Investors; Woodford Investment Management LLP	Announced
10.	98	Capital Increase 22%	Zogenix Inc.	Central Nervous System (CNS) disorders treatments developer, Central Nervous System (CNS) disorders treatments manufacturer	US		Completed

Top 20 deals by value (cont'd)

	Deal value (mil USD)	Deal type	Target	Target business description	Target country	Acquiror	Deal status
11.	85	Acquisition 70%	Hunan Xinhexin Bio Medical Co., Ltd	Biomedical research and development services provider	CN	Guangdong VTR Bio-Tech Co., Ltd	Announced
12.	84	Capital Increase 11%	Guangdong VTR Bio-Tech Co., Ltd	Feed enzyme developer, Feed enzyme manufacturer	CN	Golden Eagle Asset Management Co., Ltd; Huachuang Yiduoli Employee Growth No. 32 Asset Management Plan; Elitimes Jiuying No. 1 Fund; Mr Cai Xiaoru	Announced
13.	55	Minority stake	RaNA Therapeutics Inc.	RNA novel drugs developer company	US	Monsanto Company; The Baupost Group LLC; Brookside Capital LLC; Pfizer Venture Investments; Partners Innovation Fund; SR One Ltd; Atlas Venture Inc.; Omega Fund Management (US) Inc.; MS Ventures; Rock Springs Capital Management LP; Leerink Partners LLC; MRL Ventures Inc.; Undisclosed blue chip public investment fund	Completed
14.	45	Minority stake	Ginkgo Bioworks Inc.	Biological research developer	US	Felicis Ventures; Y Combinator LLC; OS Fund LLC	Completed
15.	36	Minority stake	GenSight Biologics SA	Retinal degenerative diseases biopharmaceuticals developer	FR	Index Venture Management SA; Fidelity Management & Research Company; Versant Venture Management LLC; Jennison Associates LLC; Perceptive Advisors LLC; Abingworth LLP; Novartis Venture Funds; Sphera Global Healthcare Master Fund; Innovative Biotherapies of Rare Diseases Fund	Completed
16.	33	Minority stake	KalVista Pharmaceuticals Ltd	Molecule plasma kallikrein inhibitors developer	GB	Novo A/S; SV Life Sciences Advisers LLP; RA Capital Management LLC; Longwood Founders Fund LP	Completed
17.	32	Capital Increase 26%	4SC AG	Cancer and autoimmune molecule pharmaceuticals research services	DE	Investors; Wellington Partners GmbH	Completed
18.	29	Capital Increase 16%	CytRx Corporation	Oncology biopharmaceuticals developer, Oncology biopharmaceuticals manufacturer	US		Completed
19.	29	Capital Increase 10%	Anthera Pharmaceuticals Inc.	Inflammatory and autoimmune diseases biopharmaceuticals developer, Inflammatory and autoimmune diseases biopharmaceuticals manufacturer	US		Completed
20.	24	Capital Increase 9%	Poxel SA	Metabolic disease drugs manufacturer, Metabolic disease research services	FR	Investors	Completed

Target countries by volume

Target country	Jul-14	Jun-15	Jul-15
US	29	32	25
China	1	12	10
UK	6	10	9
Australia	3	8	8
Poland	3	1	6
Canada	4	9	6
South Korea	6	5	5
France	3	0	5
Sweden	2	1	3
Germany	4	0	3
Spain	1	0	2
Switzerland	0	0	2
Norway	0	1	2
Japan	1	1	1
Hungary	0	0	1
Colombia	0	0	1
New Zealand	0	1	1

Target countries by value

Target country	Jul-14 (mil USD)	Jun-15 (mil USD)	Jul-15 (mil USD)
US	508	1,465	8,504
China	18	657	1,105
UK	28	109	667
Spain	0	0	319
France	1,749	0	92
South Korea	73	38	42
Australia	18	84	41
Switzerland	0	0	40
Poland	11	53	37
Germany	14	0	32
Sweden	7	4	26
Canada	14	408	26
Norway	0	9	21
Hungary	0	0	9
New Zealand	0	0	9
Japan	2	0	5

IPOs by volume and value

Announced date	No of deals	Total deal value (mil USD)
Jul-15	3	215
Jun-15	11	1,151
May-15	4	449
Apr-15	4	595
Mar-15	10	468
Feb-15	3	776
Jan-15	3	214
Dec-14	2	175
Nov-14	3	155
Oct-14	4	449
Sep-14	7	397
Aug-14	5	324
Jul-14	3	109

July IPOs

Target name	Aimmune Therapeutics Inc.	GenSight Biologics SA	Anlarop Development AG
Deal value (mil USD)	115	100	n.a.
Deal type	Planned IPO on Nasdaq	Planned IPO on Nasdaq	IPO 17.7% on Euronext Paris
Target country	US	FR	CH
Target business	Clinical-stage biopharmaceutical desensitization treatments manufacturer	Retinal degenerative diseases biopharmaceuticals developer	Air purification equipment manufacturer holding company
Announced date	06/07/2015	07/07/2015	15/07/2015
Deal status	Announced	Announced	Completed

Notes to editors

The search criteria uses a key word system based on the targets' business description

The key words and phrases are: “biotechnology” OR “antimicrobial” OR “CNS” OR “neurotransmitter” OR “cardiovascular” OR “blood system agent” OR “cell control agent” OR “dermatological” OR “genetic” OR “hormone” OR “immunomodulator” OR “Ion Channel” OR “modulat” OR “metabolic” OR “musculoskeletal” OR “renal system” OR “reproductive” OR “respiratory” OR “diagnostic” OR “gastrointestinal” OR “degeneration” OR “endocrine” OR “growth disorder” OR “gynecology” OR “obstetrics” OR “haematological” OR “neurological” OR “neoplasm” OR “neurological” OR “nutritional” OR “psychiatric” OR “toxicity” OR “ulcer” OR “genitourinary” OR “oncology” OR “biological” OR “clinical” OR “biomedical” OR “bioinformatics” OR “cheminformatics” OR “biologicgenerics” OR “genetics” OR “genomics” OR “transgenic” OR “protein” OR “RNA” OR “DNA” OR “enzyme” OR “fermentation” OR “oncogenomics” OR “proteomics” OR “nanobiotechnology” OR “Gene” OR “Central nervous system” OR “Cloning” OR “genome” OR “genotyping” OR “molecular” OR “microbiology” OR “animal cell culture” OR “biochemistry” OR “embryology” OR “cell biology” OR “Tissue Engineering” OR “Stem Cell” OR “Pharmacogenomics” OR “Escherichia Coli” OR “E. Coli” OR “Embryos” OR “molecule” OR “transgenic” OR “biotechnology” OR “biotech” OR “bio tech” OR “biopharmaceuticals” OR “micropropagation” OR “biobased products” OR “biopharming” OR “biotechnology-derived” OR “bt corn” OR “chromosomes” OR “embryonic stem cells” OR “fibroblast” OR “molecular biology” OR “mutation” OR “nucleotide” OR “organic agriculture” OR “phenotype” OR “plant-incorporated protectants” OR “pollen” OR “tissue culture” OR “transfection” OR “virus” OR “vitamin” OR “xenotransplantation” OR “zygote”

Activity is based on the activity of the target company

Deal status is announced, completed, pending or unconditional